The drug belongs to a relatively new class of human antidiabetic drugs that lower insulin concentration by inhibiting glucose resorption in the kidneys.
If your horse has been treated with an SGLT2 inhibitor (Ertugliflozin, Canagliflozin, Dapagliflozin or similar), they might be eligible to participate in a new study.